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Native IgA1, for which no crystal structure is known, contains
an O-galactosylated 23-residue hinge region that joins its Fab
and Fc regions. IgA nephropathy (IgAN) is a leading cause of
chronic kidney disease in developed countries. Because IgA1 in
IgAN often has a poorly O-galactosylated hinge region, the
solution structures of monomeric IgA1 from a healthy subject
and three IgAN patients with four different O-galactosylation
levels were studied. Analytical ultracentrifugation showed that all
four IgA1 samples were monomeric with similar sedimentation
coefficients, s020,w. X-ray scattering showed that the radius
of gyration (Rg) slightly increased with IgA1 concentration,
indicating self-association, although their distance distribution
curves, P(r), were unchanged with concentration. Neutron
scattering indicated similar Rg values and P(r) curves, although
IgA1 showed a propensity to aggregate in heavy water buffer.
A new atomistic modelling procedure based on comparisons
with 177000 conformationally-randomized IgA1 structures with
the individual experimental scattering curves revealed similar
extended Y-shaped solution structures for all four differentially-
glycosylated IgA1 molecules. The final models indicated that the
N-glycans at Asn263 were folded back against the Fc surface,
the C-terminal tailpiece conformations were undefined and hinge
O-galactosylation had little effect on the solution structure. The
solution structures for full-length IgA1 showed extended hinges
and the Fab and Fc regions were positioned asymmetrically to
provide ample space for the functionally-important binding of
two FcαR receptors to its Fc region. Whereas no link between
O-galactosylation and the IgA1 solution structure was detected,
an increase in IgA1 aggregation with reduced O-galactosylation
may relate to IgAN.
Key words: analytical ultracentrifugation, antibody, constrained
modelling, human immunoglobulin A1 (IgA1), immuno-
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INTRODUCTION
IgA is the most abundant antibody sub-class present on human
mucosal surfaces, which themselves comprise the largest surface
area in the human body exposed to pathogens [1]. Human IgA
comprises two sub-classes, IgA1 and IgA2 and most IgA exist
in monomeric or dimeric forms termed mIgA (monomeric IgA)
and dIgA (dimeric IgA) respectively [2]. The main function of
IgA is to act as the first line of defence in the genitourinary,
respiratory and gastrointestinal tracts by preventing the entrance
of pathogens into the body [1,2]. The upper respiratory and
digestive tract secretions contain more IgA1 than IgA2 [1]. In
serum, IgA is mainly monomeric and consists of approximately
90% IgA1 and 10% IgA2 [3], although the function of the two
sub-classes remains unclear [2]. The effector functions of IgA are
mediated by the Fc region, which binds the Fcα receptor (FcαR)
to clear foreign antigens by opsonization and phagocytosis [1].
The complement system is weakly activated by IgA through its
alternative and lectin pathways [4–7]. IgA nephropathy (IgAN)
is the commonest pattern of glomerulonephritis in the world and
an important cause of kidney failure with over 30% of patients
progressing to end-stage renal disease within 20 years of diagnosis
[8]. IgAN is characterized by the deposition of IgA1-containing
immune complexes in the mesangium which triggers glomerular
injury through activation of resident glomerular cells [9,10].
IgA1 and IgA2 primarily differ in their hinge region. IgA1
contains a 23-residue hinge between the Fab and Fc regions
(Figure 1), which is replaced by a short 10-residue hinge in IgA2.
The IgA1 hinge is rich in proline residues and serine/threonine
residues, the latter having the capacity for binding six O-linked
oligosaccharides on each of the two hinges. These six sites can
be occupied by α1 O-linked N-acetylgalactosamine (GalNAc)
residues which may be extended with the addition of galactose
(Gal) and sialic acid (NeuNAc) in different combinations
[11–14]. This O-galactosylation gives rise to a heterogeneous
population of IgA1 molecules in an individual [12,15–17]. The O-
galactosylation of the hinge has been implicated in IgAN, where
the IgA1 deposits are often poorly galactosylated [18]. Numerous
studies have postulated that the reduced level of O-linked IgA1
glycans in IgAN have a pathogenic role [9,19,20], however the
effects of the altered O-galactosylation upon the 3D IgA1 structure
and its function remain to be elucidated.
A molecular understanding of IgA1 function and disease
requires an atomistic solution structure for IgA1, especially for its
hinge region. There is no crystal structure for the full-length IgA1
antibody, a common issue with many antibodies and attributable
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Figure 1 The human IgA1 domain structure
(A) The schematic cartoon shows the heavy chains with variable and constant VH, CH1, CH2 and CH3 domains and the light chains with VL and CL domains. Interchain disulfide bridges
stabilize the IgA1 structure. Two conserved N-glycosylation sites occurred at Asn263 and Asn459 (). The hinge region between the Fab and Fc regions is composed of 21 residues
(222-PVPSTPPTPSPSTPPTPSPSCC-242, anchored at Pro221 and His243), with the capacity to bind six O-linked glycans on each hinge ( and ). The sites at Thr225, Thr228 and Ser232
were assumed to be occupied for the present study (; Experimental). An 18-residue tailpiece between Pro455 and Tyr472 (broken line) lies at the C-terminus of each heavy chain. (B) Ribbon diagrams
of the IgA1 Fc region (PDB code 1OW0) in two views to show the intrachain disulfide bridges between two Cys242–Cys299 pairs at the top of the Fc region. Two unpaired Cys301 residues are shown
also, which are probably bridged to Cys241 (result not shown). Also shown are Cys311 and the glycosylation site at Asn263. The two heavy chains are shown in grey and light blue. Another IgA1 Fc
crystal structure (PDB code 2QEJ; not shown) revealed different disulfide bridges (two Cys242–Cys301 pairs and a Cys299–Cys299 pair). (C) The sequence of human IgA1 is shown (Experimental).
Known disulfide bridges are indicated by vertical and horizontal lines. Asn263 and Asn459 are asterisked.
to segmental flexibility at the hinge region that hinders crystal
growth. Intact Y-shaped IgA structures were originally observed
in electron micrographs [21–23]. An extended solution structure
for human IgA1 was determined by constrained scattering
modelling, this being the first such structure determination of
this type [24]. The previous experimental data were derived from
pooled serum monomer IgA1 and was therefore heterogeneous,
and homology models and not crystal structures were used for the
scattering fits that assumed 2-fold symmetry in intact IgA1 [24]. In
the present study, the IgA1 solution structure was re-investigated
in full. First, IgA1 was purified separately from four individuals
to reduce its heterogeneity, but now targeting a broad range
of O-galactosylation levels. Second, the use of size-distribution
analyses c(s) by analytical ultracentrifugation, high-throughput
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X-ray instruments and new neutron scattering instruments with
higher fluxes provide much enhanced data sets for modelling.
Third, crystal structures for a human IgA1 Fab region [25], an
IgA Fc region in complex with FcαR [26] and an IgA Fc region
in complex with staphylococcal superantigen-like protein [27]
permit more accurate structural modelling of intact IgA1. Fourth,
although constrained scattering modelling has now been applied
to 14 intact antibodies [28,29], this method is now much enhanced
by new Monte Carlo methods that generate far larger libraries
of randomized trial structures for improved curve fits [30,31].
These four developments enabled more accurate molecular
modelling of more extensive scattering data sets for monomeric
IgA1. We obtained new molecular insights on IgA1 receptor
binding and on potential relationships between O-galactosylation
levels in the IgA1 hinge and its solution structure and IgAN
disease.
EXPERIMENTAL
Purification and composition of IgA1
Serum was obtained from one healthy subject and three patients
(denoted 2, 3 and 4) with biopsy-proven IgAN who attended
the John Walls Renal Unit, Leicester General Hospital. At
the time of serum collection, all participants had normal renal
function (estimated glomerular filtration rate > 90 ml/min). All
healthy subject and patient personal data were anonymized. The
study was approved by the Leicestershire, Northamptonshire
and Rutland Research Ethics Committee and all subjects gave
written informed consent. The four IgA1 antibodies were each
purified from serum by affinity chromatography using jacalin-
linked agarose (Vector Laboratories) [32] and dialysed against
PBS (137 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl, 1.5 mM
KH2PO4, pH 7.4) overnight at 4 ◦C. Monomeric IgA1 was isolated
from the total IgA1 preparation by FPLC chromatography using a
Superdex 200 pg column (Amersham Biosciences), concentrated
and stored at − 20 ◦C until further analysis. Immediately prior
to experiments, each IgA1 sample was further purified by gel
filtration using a Superose 6 column (Amersham Biosciences)
to remove non-specific aggregates, then concentrated using
Amicon Ultra spin concentrator (50 kDa molecular mass cut-
off) and dialysed at 4 ◦C against the appropriate measurement
buffer. Prior to measurements, IgA1 samples were stored
at 4 ◦C and were not frozen in order to avoid aggregate
formation.
The relative hinge region O-galactosylation of the four IgA1
samples was determined using an IgA1-specific enzyme-linked
Helix aspersa (HAA) lectin-binding assay with specificity for
O-linked GalNAc without Gal attached [19,32,33]. Serum IgA
was captured on to immunoplates (Nunc Life Technologies)
using anti-human IgA antibody (Dako) and overnight incubation
at 4 ◦C. The captured IgA was incubated overnight with 75
milliunits/ml neuraminidase (New England Biolabs UK Ltd)
in sodium acetate buffer, pH 5, to remove terminal NeuNAcs
residues. The desialylated IgA1 was incubated with biotinylated
HAA lectin (Sigma–Aldrich, diluted 1/500 in PBS) for 90 min
at room temperature. After washing, the samples were incubated
with peroxidase-conjugated avidin (Vector Laboratories; diluted
1/2000 in PBS). Lectin binding was measured colorimetrically
using the substrates 1,2-phenylenediamine dihydrochloride and
hydrogen peroxide on an ELISA plate reader (Titertek Multiskan)
using a 492 nm ultraviolet filter. Results were expressed as D
values, normalized to serum samples with known haemagglutinin
(HA)-lectin binding. In this assay, an increase in HAA lectin
binding to IgA1 indicated an increase in exposed O-linked
GalNAc and corresponded to reduced hinge O-galactosylation.
The samples were analysed independently in triplicate and results
reported as the mean and the S.E.M.
The human monomeric IgA1 amino acid sequence [24]
(Figure 1C) provided the molecular mass, unhydrated and
hydrated volumes, partial specific volume and absorption
coefficient for the experimental analyses. As defined in Figure 1,
the sequences of the VH and VL variable regions were taken
from the crystal structure for a human IgA Fab region (PDB
codes 3M8O) [34] and the constant region sequences CH1, CH2,
CH3 and CL were taken from our previous analysis (Uniprot
code P01876) [24]. The IgA1 samples from the healthy subject
and three IgAN patients were polyclonal and therefore contain
heterogeneous complementarity determining regions in the VH
and VL domains [15,16]. The IgA1 molecular mass was calculated
as 164 kDa, its unhydrated volume was 205.7 nm3, its hydrated
volume was 272.5 nm3 (based on a hydration of 0.3g of water
per gram of glycoprotein and an electrostricted volume of 0.0245
nm3 per bound water molecule), its partial specific volume ν
was 0.724 ml/g and its absorption coefficient at 280 nm was 12.7
(1%, 1 cm path-length) [24,35,36]. All data were recorded in
PBS in light or heavy water at 20 ◦C. The PBS buffer densities
of 1.00543 g/ml in light water and 1.11238 g/ml in 100% 2H2O
at 20 ◦C and the buffer viscosity of 0.01019 cp were calculated
using SEDNTERP [37].
Experimental data collection for IgA1
Analytical ultracentrifugation data were obtained on two
Beckman XL-I instruments equipped with AnTi50 and AnTi60
rotors. Sedimentation velocity data were acquired for all four
IgA1 samples at 20 ◦C in H2O. Healthy subject IgA1 was studied
at concentrations of 0.19, 0.32, 0.54, 0.90, 1.51 and 2.52 mg/ml;
patient 2 IgA1 was studied at concentrations of 0.41, 0.69, 1.15
and 1.93 mg/ml; patient 3 IgA1 was studied at concentrations
of 0.23, 0.39, 0.66 and 1.11 mg/ml; and patient 4 IgA1 was
studied at concentrations of 0.41, 0.68 and 1.13 mg/ml. Data
were collected at rotor speeds of 20000, 30000, 40000 and
50000 rpm in two-sector cells with column heights of 12 mm.
Sedimentation analysis was performed using direct boundary
Lamm fits of up to 150 scans using SEDFIT (version 14.1)
[38,39]. SEDFIT gave size-distribution analyses c(s) that revealed
the sedimentation species; this assumed these species to have the
same frictional ratio f/f0, where f is the frictional coefficient of
the macromolecule and f0 is the frictional coefficient of the sphere
with the same hydrated volume as the macromolecule. The final
SEDFIT analyses used a fixed resolution of 200 and optimized
the c(s) fit by floating f/f0, the baseline, the meniscus and the
bottom of the cell until the overall RMSDs and visual appearance
of the fits were satisfactory. The percentage of oligomers in the
total loading concentration was derived using the c(s) integration
function.
X-ray scattering data were obtained at 20 ◦C for the IgA1
samples in light water in a single beam session in four-bunch
mode on Instrument ID02 at the European Synchrotron Radiation
Facility, operating with a ring energy of 6.0 GeV [40]. A
sample-to-detector distance of 3.0 m was used. Data were
acquired using a fast readout low noise camera (FreLoN) with a
resolution of 512 × 512 pixels. Healthy subject IgA1 was studied
at concentrations of 0.25, 0.51, 0.76 and 1.02 mg/ml; patient 2
IgA1 was studied at 0.16, 0.33, 0.49, 0.66, 0.99 and 1.33 mg/ml;
patient 3 IgA1 was studied at 0.12, 0.24, 0.36, 0.48, 0.72 and
0.97 mg/ml; patient 4 IgA1 was studied at 0.15, 0.31, 0.47, 0.63,
0.94 and 1.26 mg/ml. This totalled 88 samples. Sample volumes
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of 100 μl were measured four times in a polycarboxylate capillary
at 2-mm diameter that avoids protein deposits during exposures,
with the samples being moved continuously during beam exposure
to reduce radiation damage. Thus data sets of 10 time-frames,
with a frame exposure time of 0.1 or 0.2 s each, were acquired in
quadruplicate as a subject of reproducibility. Online checks during
data acquisition confirmed the absence of radiation damage, after
which each set of 10 frames were averaged.
Neutron scattering data for IgA1 in heavy water buffer were
obtained on Instrument SANS2D at the pulsed neutron source
ISIS at the Rutherford Appleton Laboratory [41]. A pulsed
neutron beam was derived from proton beam currents of
approximately 40 μA. SANS2D data were recorded with 4 m
of collimation, a 4-m sample-to-detector distance, a 12-mm beam
diameter and a wavelength range from 0.175 to 1.65 nm obtained
using TOF methods. Samples were measured in circular banjo
cells with 2 mm thickness positioned in a thermostatted sample
rack set at 20 ◦C. Data was collected for healthy subject IgA1 at
concentrations of 0.43, 0.85 and 1.7 mg/ml, patient 2 IgA1 at 0.6,
1.2, 1.8 and 2.4 mg/ml, patient 3 IgA1 at 0.5, 1.0, 1.6, 2.2 mg/ml
and patient 4 IgA1 at 0.43 and 0.86 mg/ml.
For a given solute–solvent contrast, the radius of gyration (Rg) is
a measure of structural elongation if the internal inhomogeneity
of scattering densities within the protein has no effect. Guinier
analyses of the scattering curve I(Q) at low scattering vectors Q
(where Q = 4π sin θ /λ; 2θ is the scattering angle and λ is the
wavelength) gives the Rg and the forward scattering at zero angle
I(0) [42]:
ln I (Q) = ln I (0) − Rg
2 Q2
3
This expression is valid in a Q·Rg range up to 1.5. If the structure
is elongated, the mean Rg of cross-sectional structure Rxs and
the mean cross-sectional intensity at zero angle [I(Q)Q]Q→0 is
obtained from:
ln [I (Q) Q] = [I (Q) Q]Q→0 −
Rxs 2 Q2
2
The cross-sectional plot for immunoglobulins exhibits two
distinct regions, a steeper innermost one and a flatter outermost
one [43]. The two analyses are denoted as Rxs-1 and Rxs-2
respectively. The Rg and Rxs analyses were performed using an
interactive PERL script program SCTPL7 (J. T. Eaton and S.
J. Perkins, unpublished software) on Silicon Graphics OCTANE
Workstations. Indirect Fourier transformation of the scattering
data I(Q) which was measured in reciprocal space into real space
to give the distance distribution function P(r) was carried out
using the program GNOM [44]:
P (r ) = 1
2π 2
∞∫
0
I (Q) Qr sin (Qr ) d Q
P(r) corresponds to the distribution of distances r between
volume elements. This provides the maximum dimension L of
IgA1 and its most commonly occurring distance vector M in real
space. For this, the X-ray I(Q) curve utilized up to 441 data points
in the Q range between 0.13 and 2.10 nm− 1. The neutron I(Q)
curve utilized up to 45 data points in the Q range between 0.18
and 1.6 nm− 1.
Generation of a starting structural model for PTerm455
The modelling of IgA1 was initiated by two crystal structures
for the Fab and Fc regions of IgA (PDB codes 3M8O and
1OW0 respectively) [26,34]. The initial scattering data used for
modelling was that for PTerm455, a tailpiece-deleted recombinant
IgA1 with its C-terminus at Pro455 (Figure 1C) [24]. Based on
these two crystal structures, the starting PTerm455 conformation
(termed ‘assembled’) was constructed as follows.
(i) The full hinge was defined as the 21-residue segment
222-VPSTPPTPSPSTPPTPSPSCC-242, anchored at its flanking
residues Pro221 and His243. Two distinct hinge structures were
modelled using PyMOL v1.3r1 (Schrodinger) that created
Y-shaped and T-shaped PTerm455 structures. The Y-shaped
structure was generated using the PyMOL build_seq script
(PyMOL Script Repository, Queen’s University) with backbone ϕ
and ψ angles of 10◦. The T-shaped structure was generated from
our previous PTerm455 structure [24].
(ii) The C-terminal Fc pentapeptide was defined as 451-
LAGKP-455 and added to the Fc structure using the PyMOL
build_seq script.
(iii) The Asn263 N-glycan was taken to be biantennary with
both branches having the same monosaccharides [45]. Because
only one β1→6-linked NeuNAc.Gal.GlcNAc branch was visible
in the Fc crystal structure, its conformation was copied to form
a second β1→3-linked branch using PyMOL, to give a structure
of NeuNAc2.Gal2.GlcNAc2.Fuc.Man3.GlcNAc2. The appropriate
CONECT records were added for all the residues and the
glycosidic bond.
This ‘assembled’ PTerm455 structure was prepared for
energy minimization through the addition of H atoms and the
optimization of steric overlaps within the crystal structure using
the glycan reader component of CHARMM-GUI [46,47] and
the CHARMM36 force field [48–52]. Disulfide bridges were
included between Cys23–Cys93 and Cys139–Cys199 in each light
chain and Cys22–Cys98, Cys145-Cys204, Cys196-Cys220, Cys266-Cys323
and Cys369-Cys432 in each heavy chain. Interchain disulfide bridges
were formed between Cys219 in the CL domain and Cys133 in the
CH1 domain and two between Cys299 in the CH2 domain and
Cys242 in the hinge (Figure 1B). Two thousand steps of energy
minimization was performed on both Y-shaped and T-shaped
structures in generalized Born implicit solvent using the NAMD2
software for MD simulations to create two structurally varied
PTerm455 structures (termed ‘initial’) [53,54].
Generation of trial structural models for full-length IgA1
The four main conformational unknowns in the full-length IgA1
structure were each considered as follows.
(i) The Asn263 N-glycan conformations (NGs) were investigated
by a NAMD2 MD simulation of the ‘initial’ T-shaped PTerm455
structure as above, in which the protein backbone was constrained
to maintain the same conformation using a force of 4 kcal mol− 1
Å− 2 (1 cal ≡ 4.184 J). The protein backbone was held fixed in
this. The system was heated from 50 K to 300 K over 320 ps
before an equilibration run of 1 ns. To accelerate the sampling of
randomized N-glycan conformations, the system was heated from
300 K to 750 K over 580 ps and a further 2 ns run was performed.
Analysis of the glycan structures sampled during the simulation
identified two distinct non-crystal like conformers. Consequently,
a library of three N-glycan structures, denoted NG0–NG2, was
produced to be added symmetrically to both Fc chains in all global
PTerm455 models.
(ii) Trial hinge conformations in the ‘initial’ PTerm455
structure were computed using the Monte Carlo simulation
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module in SASSIE [31]. The backbone ϕ and ψ angles of
the 20 peptides in the 21-residue hinge (222-VPSTPPTP-
SPSTPPTPSPSCC-242) and the four peptides in the five-residue
C-termini (451-LAGKP-455) were randomized independently
of one another. Monte Carlo runs for each of the ‘initial’ Y-
shaped and T-shaped PTerm455 models used maximum ϕ and
ψ rotational steps of up to 10◦ and 30◦ respectively from
the previous values, giving 57611 conformations. Each of the
three N-glycan conformations NG0-NG2 from (i) above were
attached to the 57611 conformations using SASSIE SASmol
scripts [31] to give 172833 trial PTerm455 models. PTerm455
curve fits based on an R factor filter of less than or equal to
7% reduced this total to 36621 models for the next modelling
stage.
(iii) The C-terminal tailpiece 456-THVNVSVVMAEVDG-
TCY-472 and an Asn459 N-glycan were added to the ‘initial’
T-shaped PTerm455 model to create the full-length IgA1 structure
(Figure 1A). This was achieved with the PyMOL build_seq script.
A standard biantennary glycan was used for Asn459 [24,45],
making a total of 2 × 28 amino acid and glycan residues. The
resulting full-length IgA1 structure was processed using the
CHARMM-GUI glycan reader as above. In the MD simulation,
the IgA1 structure was energy minimized using NAMD2 for 2000
steps before being heated from 50 K to 300 K over 320 ps. After
this, an equilibration run of 1 ns was performed, followed by
a further 2 ns of production simulation. In all simulations, the
protein backbone was constrained to remain close to the starting
structure using a force of 4 kcal mol− 1 Å− 2 except for the C-
terminal tailpiece 451-LAGKPTHVNVSVVMAEVDGTCY-472
which was allowed to move freely. Principal component analysis
using the Bio3D package [55] identified four distinct tailpiece
structures TP1–TP4, each of which were superimposed upon the
36621 PTerm455 models using the main chain atoms of Arg450 to
give 146484 full-length IgA1 models.
(iv) Six NeuNAc.Gal.GalNAc O-glycans were added to the two
hinges of the 146484 IgA1 models, these being representative of
reported O-glycan structures [56,57]. They were located at Thr225,
Thr228 and Ser232 as the most highly populated sites of the six
potential sites at Thr225, Thr228, Ser230, Ser232, Thr233 and Thr236
[17,56,57]. This was achieved by overlapping the backbone and
β-carbon atoms of the linked serine/threonine residue connected
to an extended O-linked trisaccharide conformation using
PyMOL.
Scattering curve calculation using SCT
Scattering curves were calculated using the recently-released
open source SCT software suite [58]. Unhydrated scattering
curves were computed from the 172833 trial PTerm455 models
for comparison with the PTerm455 neutron scattering curve in
heavy water [24]. Hydrated scattering curves were computed
from the 146484 trial full-length IgA1 models for comparison
with the experimental X-ray scattering data. The atomic co-
ordinates were coarse grained into small sphere models using
a grid with cube-side length of 0.530 nm and a cut-off of four
atoms; these parameters were optimized by SCT to reproduce the
unhydrated protein volume. The hydration shell corresponding to
0.3 g of water per gram of protein was created by adding hydration
spheres [35,58,59]. Scattering curves I(Q) were calculated using
the Debye equation adapted to spheres [60]. Each experimental
I(Q) value was matched to the theoretical calculated I(Q) value
with the closest Q value, after which the R factor was computed
by analogy with crystallography where lower R factors represent
better fits:
R f actor =
∑∥∥‖IExpt (Q)‖ − η‖IT heor (Q)‖∥∥∑ ‖IExpt (Q)‖ × 100
η is a scaling factor used to match the theoretical curve to
the experimental I(0) value. An iterative search to minimize the
R factor was used to determine η. This procedure was applied
twice, namely to the 172833 PTerm455 models to analyse the
N-glycan conformations NG0–NG2 and the 146484 full-length
IgA1 models to analyse the four tailpiece conformations TP1–
TP4. Principal component analysis using the Bio3D package [55]
identified four distinct clusters of full-length IgA1 structures FL1–
FL4. A representative best-fit atomistic model and all 112 models
of the FL3 cluster are available from Supplementary Materials.
The best-fit FL1, FL2, FL3 and FL4 structures corresponded to
frames 51, 46, 62 and 52 of the 54, 152, 112 and 153 structures
respectively in these files.
RESULTS
Purification and characterization of four IgA1 samples
Four individuals were selected to permit the study of a wide range
of O-galactosylation contents in IgA1. One healthy subject and
three patient IgA1 samples were purified from their serum using
lectin jacalin affinity chromatography (Experimental), followed
by gel filtration immediately prior to the ultracentrifugation or
scattering experiments to ensure that IgA1 was monodisperse.
IgA1 was found to aggregate if stored frozen. In all four cases,
IgA1 eluted as a principally symmetric main peak at 14.5 ml
(Figure 2). These showed a single band between 200 and 116 kDa
in non-reducing SDS/PAGE that corresponds to the expected
masses of ∼160 kDa for intact IgA1 [61]. Under reducing
conditions, the heavy chains migrated at between 55 and 66 kDa
and the light chains migrated at between 21.5 and 31 kDa. These
bands corresponded to the α-heavy chain of ∼62 kDa and κ/λ
light chains of ∼30 kDa as expected (Figure 2). The HAA lectin-
binding assay (Experimental) revealed that the healthy subject
IgA1 had a median hinge O-galactosylation profile (HAA lectin
binding = 1.11 mean D492; S.E.M. +− 0.04), whereas IgAN patients
2 and 4 displayed poor hinge region O-galactosylation (high
HAA lectin binding = 1.18 and 1.29 mean D492 respectively;
both S.E.M +− 0.04) and patient 3 showed a low HAA lectin
binding (1.00 mean D492; S.E.M. +− 0.03) that corresponded to
more extensive O-linked galactosylation. Changes in the pattern
of IgA1 O-glycosylation are the most consistently observed
pathological feature in populations of IgAN patients from North
America, Europe and Asia; however, there is a broad spread in
O-glycosylation levels. Patients 2 and 4 showed lower levels of
O-galactosylation which is more commonly observed in IgAN,
whereas patient 3 showed a less common higher O-galactosylation
which predisposes to non-progressive IgAN disease. The four
IgA1 samples thus displayed a broad range of O-glycan contents.
Analytical ultracentrifugation of the IgA1 samples
Sedimentation velocity experiments examined the shape and mass
of the four IgA1 samples. The SEDFIT analyses of 17 separate
IgA1 runs in concentration ranges between 0.19 and 2.52 mg/ml
in PBS buffer (Experimental) involved fits of as many as 150
scans and the good agreement between the experimental boundary
scans and fitted lines is clear (left panels; Figure 3). The size
distribution analyses c(s) showed that all four IgA1 samples were
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Figure 2 Purification of human IgA1
The elution of monomeric IgA1 from the healthy subject and three IgAN patients from a Superose 6 10/300 gel filtration column is shown in the four left panels (mAU, milli-absorbance units),
together with molecular mass markers (kDa). The non-reduced and reduced SDS/PAGE analyses of IgA1 are shown in the two right panels with H representing the heavy chain and L representing the
light chain. M denotes the molecular mass markers. Lanes 1–4 represent the healthy subject and patients 2, 3 and 4 respectively. Patients with high and low HAA lectin-binding values are labelled
as ‘high’ and ‘low’ respectively here and in Figures 3–6 below.
predominantly monomeric in solution and all were accompanied
by a minor dimer peak. The monomer peak was observed at s020,w
values of 6.2–6.4 S for all four IgA1 samples. These s020,w values
were consistent with previously reported values of 6.1–7.0 S for
human IgA1 [24,45,61,62]. The IgA1 sedimentation rates did not
depend on the concentration (Figure 3E). For 1.51 mg/ml healthy
subject IgA1, the monomer s020,w values were similar at 6.27 S
for 20000 rpm, 6.25 S for 30000 rpm and 6.20 S for 40000 rpm,
thus almost no dependence on rotor speed was seen that would
otherwise imply the existence of very flexible hinge regions. All
the IgA1 data reported in this study were for 30000 rpm. The
average s20,w values of the IgA1 monomer were 6.32 +− 0.11 S(healthy subject), 6.20 +− 0.14 S (patient 2), 6.25 +− 0.06 S (patient
3) and 6.35 +− 0.05 S (patient 4; Table 1A). The s020,w values of
IgA1 were similar within error showing that IgA1 is stable and
reproducible in shape for all four samples. The c(s) analyses
indicated that the average molecular masses of the monomer IgA1
peaks were 168 +− 12 kDa (healthy subject), 153 +− 24 kDa (patient
2), 174 +− 4 kDa (patient 3) and 163 +− 20 kDa (patient 4) in PBS
in H2O. These agreed well with the expected molecular mass of
IgA1 of ∼160 kDa [62], although that for IgA1 from patient 3 was
slightly higher. Integration of the monomer and dimer c(s) peaks
showed high amounts of monomeric IgA1 with mean values of
93.2% (healthy subject), 94.7% (patient 2), 93.2% (patient 3)
and 94.4% (patient 4; Figure 3F). No concentration dependence
was detected in Figures 3(E) and 3(F).
The minor dimer peak seen in the c(s) analyses occurred at s020,w
values between 8 S and 12 S (Figure 3E). The s020,w values of the
IgA1 dimer were 9.82 +− 0.62 S (healthy subject), 9.56 +− 1.29
S (patient 2), 10.21 +− 0.26 S (patient 3) and 10.38 +− 0.41 S(patient 4) in PBS at 20 ◦C. Although small in size and not
accurately measured, this peak occurred at mean molecular
masses of 326 +− 33 kDa (healthy subject), 288 +− 40 kDa (patient
2), 364 +− 15 kDa (patient 3) and 338 +− 30 kDa (patient 4). These
masses are consistent with the formation of small amounts of an
IgA1 dimer from the non-covalent association of two monomers
with an expected mass of ∼320 kDa. The minor amount of
dimer did not detectably alter with concentration and amounted
to approximately 3%–5% or less of the total IgA1 content
(Figure 3F).
X-ray and neutron scattering of the IgA1 samples
X-ray scattering with light water buffer monitored the shape of the
hydration shell surrounding IgA1, as well as its overall antibody
structure, whereas neutron scattering with heavy water buffer
monitored the overall shape of the unhydrated structure because
the hydration shell was largely invisible in this buffer [59]. The
heavy water buffer also monitored potential IgA1 self-association,
because heavy water is associated with weaker solute–solvent
hydration.
A total of 88 separate runs were measured by X-ray scattering
for the four IgA1 samples at 20 ◦C in concentration ranges
between 0.12 and 1.33 mg/ml. Guinier analyses resulted in high-
quality linear plots in three distinct regions of the I(Q) curves,
as expected for antibodies, from which the Rg, Rxs-1 and Rxs-2
values were obtained within satisfactory Q·Rg and Q·Rxs limits
(Figure 4A; Table 1A). The lack of upward curvature in the
Guinier plots at low Q values indicates the absence of non-
specific aggregates. When plotted together, this extensive set
of X-ray Rg values for the four IgA1 samples was sensitive to
the concentration, unlike the sedimentation data. The X-ray Rg
values of IgA1 increased with increasing concentration from 6.05
to 6.25 nm for healthy subject, 6.03 to 6.49 nm for patient 2,
6.04 to 6.30 nm for patient 3 and 5.99 to 6.39 nm for patient 4
(Figure 5A). Extrapolation to zero concentration resulted in very
similar Rg values of 5.96 nm (healthy subject), 5.92 nm (patient 2),
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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Figure 3 Sedimentation velocity analyses of IgA1
The experimentally observed sedimentation boundaries for IgA1 samples from (A) the healthy subject and (B–D) patients 2, 3 and 4 in PBS-137 were recorded at a rotor speed of 30000 rpm and
20◦C. Approximately 30 boundaries (black outlines) are shown for up to 150 scans at intervals of about every fifth scan for clarity, fitted using SEDFIT as shown (thin white lines). The right panel
shows the size-distribution analyses c(s), revealing a monomer (M) peak at s20,w values of 6.2 – 6.3 S for the four IgA1 samples. Small amounts of a dimer (D) were detectable at ∼9 S. (E) The s20,w
values for monomeric and dimeric IgA1 are shown as a function of IgA1 concentration (healthy subject, , —; patient 2,, − − ; patient 3,, - - -; patient 4,, ···). (F) The percentages of
monomer and dimer in each IgA1 sample from integration of the c(s) analyses are shown.
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
174 G.K. Hui and others
Figure 4 X-ray and neutron Guinier Rg and Rxs analyses for IgA1
(A) The X-ray scattering curves from bottom to top for 0.25, 0.51, 0.76 and 1.02 mg/ml of IgA1 from the healthy subject; 0.33, 0.49, 0.66, 0.99 and 1.33 mg/ml of IgA1 from patient 2; 0.36, 0.48,
0.72 and 0.97 mg/ml of IgA1 from patient 3; and 0.31, 0.47, 0.63, 0.94 and 1.26 mg/ml of IgA1 from patient 4, all measured at 20◦C in PBS-137. The filled circles between the arrowed data points
represent the Q·Rg and Q·Rxs ranges used to determine the Rg and Rxs values. The Q-ranges for the Rg values was 0.13–0.25 nm− 1. The Q-ranges for the Rxs-1 and Rxs-2 values were 0.28–0.51
nm− 1 and 0.56–1.01 nm− 1 respectively. (B) The neutron scattering curves from bottom to top for 0.43, 0.85 and 1.7 mg/ml of IgA1 from the healthy subject and 0.5, 1.0, 1.6 and 2.2 mg/ml of
IgA1 from patient 3 are shown for PBS-137 buffer in 2H2O at 20◦C. The Q range used for the Rg values was 0.18–0.28 nm− 1 and those for the Rxs-1 and Rxs-2 values were 0.28–0.51 nm− 1 and
0.56–1.04 nm− 1 respectively.
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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Table 1 Experimental X-ray and neutron scattering and sedimentation coefficient data for human IgA1
Extrapolated Rg (nm) Rg range (nm)* Mean Rxs-1 (nm)* Mean Rxs-2 (nm)* L (nm) s020,w (S)†
(A) X-ray data‡
Healthy subject (14 curves) 5.96 5.93–6.30 2.46 +− 0.06 1.57 +− 0.07 21.2 +− 1.3 6.32 +− 0.11
Patient 2 (21 curves) 5.92 5.58–6.52 2.50 +− 0.06 1.55 +− 0.04 22.1 +− 1.6 6.20 +− 0.14
Patient 3 (19 curves) 5.93 5.70–6.32 2.46 +− 0.05 1.58 +− 0.07 21.3 +− 1.5 6.29 +− 0.10
Patient 4 (22 curves) 5.92 5.77–6.44 2.46 +− 0.04 1.54 +− 0.05 21.0 +− 1.4 6.35 +− 0.05
Overall average§ 5.93 +− 0.02 n.a. 2.48 +− 0.08 1.58 +− 0.13 21.2 +− 1.5 6.29 +− 0.11
(B) Neutron data*
Healthy subject (3 curves) n.a. 6.10 +− 0.26 1.99 +− 0.06 1.37 +− 0.06 20.9 +− 5.1 n.a.
Patient 3 (4 curves) n.a. 6.36 +− 0.23 2.25 +− 0.08 1.49 +− 0.06 18.6 +− 1.3 n.a.
Overall average§ n.a. 6.25 +− 0.26 2.13 +− 0.15 1.44 +− 0.08 19.6 +− 3.3 n.a.
*The range of X-ray values observed from the Guinier Rg analyses is shown. In all other cases, the mean Rg, Rxs-1 and Rxs-2 values are shown.
†The mean s020,w values from the ultracentrifugation experiments at 30,000 rpm are shown.
‡The 76 experimental X-ray scattering curves exclude the concentrations below 0.25 mg/ml that were not used in the extrapolations to zero concentration (Experimental).
§The overall averages from all the experimental data sets are shown.
n.a., not applicable.
5.93 nm (patient 3) and 5.92 nm (patient 4), once the noisier
data from samples below 0.25 mg/ml were excluded (Table 1A).
The corresponding I(0)/c values for IgA1 also increased with
increase in concentration (Figure 5A). When combined with the
c(s) analyses (Figure 3F), the increases in the Rg and I(0)/c
values indicated weak non-covalent dimer formation that showed
small increases with increased concentration. The Rxs-1 and Rxs-2
values of the four IgA1 samples were unchanged. The mean Rxs-1
values were 2.46 +− 0.06 nm, 2.50 +− 0.06 nm, 2.46 +− 0.05 nm and
2.46 +− 0.04 nm and the mean Rxs-2 values were 1.57 +− 0.07 nm,
1.55 +− 0.04 nm, 1.58 +− 0.07 nm and 1.54 +− 0.05 nm, for the
healthy subject, patient 2, patient 3 and patient 4 respectively
(Table 1A). These Rg, Rxs-1 and Rxs-2 values were similar to the
Rg, Rxs-1 and Rxs-2 values of 6.20 +− 0.13 nm, 2.20 +− 0.26 nm and
1.56 +− 0.16 nm respectively from limited data from seven runs for
pooled human IgA1 [24]. However the concentration dependence
seen in the much larger data set of 88 values of Rg and I(0)/c
by the present study is novel. The X-ray data showed that,
despite the wide variation in O-galactosylation, all four IgA1
samples exhibited closely similar extended overall structures.
This outcome agreed with the sedimentation data (Figure 3F)
and implied that the overall hinge conformation in the four IgA1
samples were similar.
For neutron scattering, the full-length IgA1 samples in PBS
buffer in 100% 2H2O were analysed between 0.43 and 2.4 mg/ml.
Only the neutron Guinier analyses for IgA1 from the healthy
subject and patient 3 with high O-galactosylation revealed
satisfactory linear Rg, Rxs-1 and Rxs-2 fits as described above
for X-rays (Figure 4B). The two IgA1 samples with low O-
galactosylation showed non-specific aggregation and no Guinier
analyses were possible. Aggregation of plasma glycoproteins
in heavy water correlates with weaker solute–solvent hydrogen
bonding interactions. The seven neutron Rg values for IgA1
from the healthy subject and patient 3 were unchanged with
concentration at 20 ◦C with average values of 6.10 +− 0.26 nm
and 6.36 +− 0.23 nm (Table 1B). Because these Rg values were
slightly larger than the X-ray values, this suggested that the two
samples were not completely aggregate-free. The Rg and I(0)/c
values did not reveal a concentration dependence, attributed to the
availability of fewer data points (Figure 5B). The mean neutron
Rxs-1 values of 1.99 +− 0.06 nm and 2.25 +− 0.08 nm were similar
and the mean Rxs-2 values of 1.68 +− 0.07 nm and 1.83 +− 0.08 nm
were similar also (Figure 5B). The neutron Rxs-1 values were lower
than the X-ray Rxs-1 values and attributed to the near-invisible
hydration shell by neutrons, whereas the neutron and X-ray Rxs-2
values were more similar to each other (Table 1). The present
Guinier data were similar to the previously reported neutron
Rg, Rxs-1 and Rxs-2 values for pooled IgA1 of 6.11 +− 0.18 nm,
2.17 +− 0.23 nm and 1.18 +− 0.12 nm respectively [24].
The distance distribution function P(r) provides structural
information on full-length IgA1 in real space, this being
equivalent to a histogram of all the distances between the atoms
in IgA1. The Rg values from the X-ray P(r) analyses (result not
shown) were similar to those from the X-ray Guinier analyses,
showing that the two analyses were self-consistent. The maximum
length L of IgA1 was determined from the value of r when
the P(r) curve intersects zero at large r. The L values were
21.2 +− 1.3 nm for the healthy subject, 22.1 +− 1.6 nm for patient
2, 21.3 +− 1.5 nm for patient 3 and 21.0 +− 1.4 nm for patient 4(arrowed; Figure 6A). The L values increased to 23 nm with
increasing concentration for IgA1 from the healthy subject and the
three patients, this being consistent with weak dimer formation.
The two maxima M1 and M2 in the P(r) curves correspond to
the most frequently occurring interatomic distances within the
structure. The M1 peak corresponded mostly to distances that
arose within each of the three Fab and Fc regions (Figure 1A),
whereas the M2 peak corresponded mostly to distances between
the Fab–Fab and Fab–Fc pairs. These two peaks were identified
at approximately 4.5 nm and 8.0 nm respectively (Figure 6C).
No concentration dependence in the positions of peaks M1 and
M2 was observed and the four IgA1 samples showed similar M1
and M2 values, indicating that the IgA1 structure was unchanged
with concentration or O-galactosylation. The current X-ray data
resembled those for pooled human IgA1 but with a lower M1 of
3.7 nm and a higher M2 of 8.9 nm [24].
The neutron P(r) analyses of the two IgA1 samples in heavy
water gave Rg values similar to their observed Guinier Rg values
and did not change with increasing concentration. The mean
neutron L value was 19.6 +− 3.3 nm, being 21 nm for IgA1 from the
healthy subject and 22 nm for IgA1 from patient 3 (Figure 6B) and
were similar to the X-ray L values above. The two peaks M1 and
M2 were identified at approximately 4.5 nm and 9 nm respectively
in the neutron P(r) curves (Figures 6B and 6D). The positions of
M1 and M2 did not change with concentration. Although the
X-ray and neutron M1 values were the same, the neutron M2
values were higher than the X-ray M2 values above. In summary,
our extensive data sets for four IgA1 samples provided a sound
basis for new molecular modelling of the IgA1 solution structure
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
176 G.K. Hui and others
Figure 5 Concentration dependence of the Guinier values for IgA1
(A) The X-ray Rg, I(0)/c, Rxs-1 and Rxs-2 values for the four IgA1 samples were each measured in quadruplicate and averaged to give the mean +− S.D. Error bars are shown only when visible. The
values correspond to the healthy subject (,—), patient 2 (, − − ), patient 3 (, - - -) and patient 4 (, ···). The Rg and I(0)/c data were fitted by linear regression, whereas the Rxs-1 and Rxs-2
data were fitted using their mean value. (B) The neutron Rg, I(0)/c, Rxs-1 and Rxs-2 values for IgA1 each correspond to a single measurement in PBS-137 (2H2O). The fitted lines for IgA1 from healthy
subject (,—) and patient 3 (, - - -) correspond to the mean values.
and revealed no conformational differences between IgA1 with
different O-galactosylations.
Neutron scattering modelling of PTerm455
Atomistic solution structures for IgA1 were determined by
creating a large conformational library of structurally-accurate
models, from which theoretical scattering curves were generated
for comparison with the experimental scattering curve [28,29].
This atomistic modelling was initiated from the IgA Fab and Fc
crystal structures (Experimental). The four principal unknowns
in the IgA1 modelling were the conformation of (i) the two N-
glycans at Asn263, (ii) the two hinges between the Fab and Fc
regions, together with the two C-terminal tailpieces and their
Asn459 N-glycans and the six O-glycans in the two hinges.
IgA1 was first modelled in terms of its structure without its
tailpieces in order to focus on its Asn263 glycans and hinges.
This modelling was made possible because good quality neutron
scattering data were previously available for PTerm455, which
is a tailpiece-deleted recombinant IgA1 that terminated at Pro455
(Figure 1C) [24].
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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Figure 6 X-ray and neutron distance distribution analyses P(r) for IgA1
In the P(r) analyses, the peak maxima at M1 and M2 and the averaged maximum length of IgA1 at L are arrowed. (A) The X-ray P(r) curves for the four IgA1 samples are shown for concentrations
between 0.25–1.33 mg/ml, based on the same curves shown in Figure 4(A). (B) The neutron P(r) curves for two IgA1 samples in PBS-137 (2H2O) buffer are shown for concentrations between
0.43–2.2 mg/ml based on the same curves shown in Figure 4(B). (C) The concentration dependences of the maxima M1 and M2 in the X-ray P(r) curves of (A) are shown. The symbols and lines for
the healthy subject and three patient samples follow those in Figure 5(A). In all cases, the lines represent the mean values. (D) The corresponding concentration dependences of the maxima M1 and
M2 in the neutron P(r) curves of (B) are shown, following the same symbols and lines as in Figure 5(B).
(i) Firstly, two ‘initial’ T- and Y-shaped PTerm455 structures
were generated and optimized using energy minimization (Exper-
imental). These initial models contained the crystallographically-
observed compact N-glycan conformations at Asn263 (PDB code
1OW0) in hydrogen-bond contact with the Fc surface. This
conformation was denoted as NG0 (Supplementary Figure S1A).
Two more alternate extended conformations were identified from
MD simulations and denoted as NG1 and NG2 (Supplementary
Figures S1C and S1D).
(ii) Secondly, randomization of the 20 backbone ϕ and ψ angles
in the 21-residue hinge of PTerm455 generated trial PTerm455
structures, to which each of the NG0, NG1 and NG2 glycan
conformers were added. Analysis of the resulting 172833 models
showed that the lowest R factors corresponded to modelled Rg
values that were close to the experimental neutron Rg value of
5.84 +− 0.18 nm as desired [24]. These arose from the PTerm455
structures with the NG0 glycan (blue in Supplementary Figure
S2). The curve fits thus did not favour the extended NG1 and
NG2 N-glycan conformers.
X-ray scattering modelling of full-length human IgA1
Trial full-length IgA1 structures were constructed from the
best 36621 PTerm455 models (inset, Supplementary Figure S2).
To these, four distinct glycosylated tailpiece structures TP1–4
were added to give 146484 full-length candidate IgA1 models
(Supplementary Figure S3). Because the two tailpieces contribute
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
178 G.K. Hui and others
Figure 7 Outcome of the constrained modelling analyses of the full-length IgA1 solution structures including the tailpiece
(A) The four experimental X-ray I(Q) curves for the healthy subject and patients 2, 3 and 4 extrapolated to zero concentration are shown (circles), together with the fitted I(Q) curves used for the
calculation of the P(r) curves (white or black lines). Beneath these, the three difference curves obtained by subtracting the I(Q) curve for the healthy subject from that for each of the I(Q) curves
for patients 2, 3 and 4 are shown in the same colour scheme and compared with a black dashed line as reference. (B) The four X-ray P(r) curves calculated from the four extrapolated I(Q) curves
in (A) for the healthy subject and patients 2, 3 and 4 are shown, with the peak positions of M1 and M2 and the maximum dimension L labelled as arrowed. (C) The goodness-of-fit R factors for
the calculated I(Q) curves for 146484 hydrated IgA1 structures compared with the extrapolated I(Q) curve for the healthy subject is plotted against the calculated Rg value for each hydrated model.
These IgA1 structures do not contain the six O-glycans. The experimental Rg value of 5.77 +− 0.04 nm (Table 2) is denoted by a vertical blue line, together with a coloured band that indicates the+−10 % range of X-ray Rg values used for filtering of the best-fit models. In the inset, an expanded view is shown for the R factors below 10 %. (D) The 3520 IgA1 structures showing R factors below
10 % from (C) were modified by the addition of the six O-glycans to their two hinges. The R factors were recomputed using the extrapolated experimental I(Q) curve for the healthy subject. Other
details follow (C). The inset expands the data set below 7 %. (E) The two experimental neutron I(Q) curves for the healthy subject and patient 3 extrapolated to zero concentration are shown (circles),
together with the fitted I(Q) curves used for the calculation of the P(r) curves (black lines). Beneath these, the difference curve obtained by subtracting the I(Q) curve for the healthy subject from that
for patient 3 is shown. (F) The two neutron P(r) curves calculated from the extrapolated I(Q) curves for the healthy subject and patient 3 are shown.
less than 4% of the IgA1 structure, taking the best 21% of
the PTerm455 models for this step is expected to provide an
abundance of models that will include the best R-factors for intact
IgA1. Many of the PTerm455 conformations excluded by the
initial filter had very different Rg values from those selected,
making it unlikely that these models would provide good fits to
the X-ray curves.
Similar s20,w and X-ray and neutron Rg values were seen
for all four IgA1 samples (Figures 3E, 5A and 5B). Because
concentration dependences were visible in Figure 5(A) and
trace amounts of dimers were detected in the s20,w analyses
(Figure 3F), the full X-ray scattering curves were extrapolated
to zero concentration to reduce any perturbations caused by these
concentration effects. To follow the linear extrapolation of the Rg
and I(0) values (Figures 5A and 5B), curve extrapolations were
based on the best-fit regression lines plotted through the observed
I(Q) values at each Q value for each curve in the concentration
series. The subtraction of the extrapolated healthy subject X-ray
and neutron curves from the extrapolated patient curves showed
no significant features that would have indicated conformational
differences between the four IgA1 samples (Figures 7A and 7E).
The four X-ray and two neutron P(r) curves also showed close
agreements (Figures 7B and 7F). When all four extrapolated X-ray
scattering curves were modelled with the 172833 IgA1 models, all
four R-factors compared with Rg graphs were similar (Figure 7C).
Interestingly, even though IgA1 has two long 23-residue hinges of
maximum length 8.44 nm between the flanking α-carbon atoms
of Pro221 and His243, the best fit IgA1 structures showed that these
hinges were not maximally extended and had hinge lengths of
3.68 nm to 6.13 nm. These similarities between the four IgA1
samples showed that the variation in O-glycan contents had no
effect on the length of the IgA1 hinge.
Principal component analysis was used to determine the major
conformations for IgA1. A total of 471 best-fit structures showed
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Figure 8 Principal component analysis of the best-fit full-length IgA1 models
Models included in this analysis have R factors of less than 7 % when compared with the healthy subject and three patient samples and their Rxs-1 values were within 10 % of the experimental values.
(A) Conformational variability of the best-fit models from PC analysis. (B and C) Projections for each snapshot of the simulation trajectory shown as a function of PC1, PC2 and PC3. The resulting
best-fit structures for full-length IgA1 are shown as FL1–4, in which black denotes FL1, red denotes FL2, green denotes FL3 and blue denotes FL4. (D–G) The curve fits for four representative
structures for full-length IgA1 are shown for each of the four conformational clusters FL1–4 in that sequence. In each panel, the IgA1 structure is shown (Fab in red and blue; Fc in grey and light
blue), together with the calculated I(Q) and P(r) curves in red, which are compared with the experimental data in black. The R-factor for each of the curves is given in Table 2.
R-factors below 7% and Rg and Rxs-1 values within 10% of
the experimental values. The first three principal components
(PCs; PC1, PC2 and PC3) accounted for 96.7% of the variation
between these structures (Figure 8A). Hierarchical clustering of
PC1, PC2 and PC3 identified four groups of best-fit structures
FL1–4 (Figures 8B and 8C). Their X-ray Rg values agreed
well with the experimental Rg value of 5.80 nm from the
extrapolated scattering curve (Table 2). The R-factors for the
112 FL3 structures were the lowest at 5.4%–5.9% (Table 2).
The visual agreement between the experimental and modelled
I(Q) curves was the best for FL3, notably at large Q values
between 0.6–1.2 nm− 1 (Figure 8F). The modelled P(r) curve
for FL3 showed the double peaks M1 and M2, whereas those
for FL1, FL2 and FL4 showed too pronounced a double peak
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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Figure 9 Neutron curve fit using the best-fit FL3 IgA1 structure
The neutron fit corresponding to the X-ray fit of Figure 8(F) is shown. The calculated I(Q) curve
is shown as a red line, which is compared with the experimental data points in black. A flat
incoherent scattering correction of 1.5 % of I(0) was applied to the calculated curve to allow for
the proton content of the IgA1 neutron sample.
(Figures 7B, 8D–8G). Thus the FL3 best-fit structures described
best the average IgA1 solution structure as a compact Y-shape
(Figure 8F).
Comparison of the most representative FL1–4 structures closest
to the centroid of each cluster showed that the Fab regions were
conformationally similar in the FL2 and FL3 structures, differing
only by a displacement of the two Fab regions relative to the Fc
region. In the most representative FL1 and FL4 structures, the
Fab arrangements were very similar to each other (Figure 8B).
The median FL1–4 structures showed different Fc orientations
(Figures 8D–8G). Thus the modelling was unable to define a
single Fc orientation relative to the Fab regions, although all four
of FL1–4 indicated an overall Y-shaped structure for the two Fab
regions relative to Fc.
To evaluate the effect of O-galactosylation levels in IgA1, six
O-glycans at Thr225, Thr228 and Ser232 were added to the two
hinges of the 471 FL1–4 best-fit structures (Experimental). These
contribute ∼1% of the residues in IgA1. For FL3, the 112 R-
factors were 4.8%–6.2% for the healthy control, which were
improved compared with that of 6.5% for models without O-
glycans (Figure 7D). Similar improvements were seen for FL1,
FL2 and FL4 and the other three samples. Although the addition
of additional scattering density at the IgA1 hinge improved the
fits, the similarity of the four IgA1 scattering curves showed that
these were unaffected by altered O-galactosylation levels.
As an independent control of the X-ray fits, the 471 FL1–4 best-
fit models were used to compute the s020,w values for comparison
with the experimental value of 6.29 +− 0.11 S. The mean s020,w
values were 6.41 S, 6.56 S, 6.84 S and 6.69 S for FL1, FL2, FL3
and FL4 respectively (Table 2), with a mean value of 6.56 +− 0.58
S. Given that the experimental and calculated values generally
agree within +− 0.21 S [28], it was concluded that all four FL1–
4 best-fit structures were consistent with the experimental s020,w
values.
As a further independent control of the X-ray fits, the neutron
data for IgA1 were also fitted to the unhydrated 146484 full-length
IgA1 models. The 100 best fit models with the lowest R-factors
of 8% displayed Rg values close to 5.5 nm, indicating that the
mean experimental Rg value of 6.25 +− 0.26 nm corresponded to
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Figure 10 Binding of the FcαR receptor to a best-fit full-length IgA1 model
(A and B) Face-on and side-on views of the Fc region in a best-fit Y-shaped IgA1 structure are shown, taken from the median of the FL3 cluster of Figure 8. The two views are rotated by 90◦ about a
vertical axis, with the two FcαR sites on the Fc region bound to two FcαR receptors (orange: PDB code 1OW0). The two Fab regions are shown in red and blue and the Fc region is shown in grey
and light blue. The N-glycans at Asn263 and Asn459 in the Fc region and tailpiece respectively and the O-glycans at Thr225, Thr228 and Ser232 in the hinge are shown as green sticks. This structure is
also shown in the Supplemental Movie S1. (C) View of the 112 IgA1 models in the FL3 cluster, all of which were superimposed on the Fc region. The view was orientated to show the spread of the
tailpiece and 2 × 112 best-fit Fab conformations. The median structure of the FL3 cluster (frame 62) is shown as a cartoon ribbon; the other 111 models are shown as lines.
slightly aggregated IgA1 in heavy water. The best neutron curve
fit showed poorer signal-noise ratios than the X-ray fits of Figure 8
(Figure 9). Nonetheless the fair agreement with the best-fit X-ray
models and the satisfactory neutron R factors (Table 2) showed
that the neutron fits were compatible with the X-ray fits.
DISCUSSION
Our abundant X-ray scattering data from improved instrument-
ation for four human IgA1 samples with a range of hinge
O-galactosylations, together with a new modelling procedure,
resulted in atomistic Y-shaped solution structures for IgA1
(Figure 10C). Our asymmetric extended IgA1 solution structures
in combination with the crystal structure of the Fc–FcαR receptor
complex [26] show that the Fab regions in IgA1 were positioned
well away from its Fc region (Figures 10A and 10B). The exposed
Fc region is thus able to interact readily with its FcαR receptor
(Supplementary Movie S1). During this investigation, IgA1 was
found to be prone to non-specific aggregation or self-association
and its relationship with the level of hinge O-galactosylation may
be relevant to the onset of IgAN.
Solution structure of monomeric human IgA1
The three new analytical ultracentrifugation and X-ray and
neutron scattering analyses for four IgA1 samples, including three
from IgAN patients, have notably extended our understanding of
the IgA1 solution structure.
(i) In the present study, 17 ultracentrifugation runs were
performed on IgA1 from the four donors. Here, our use of
c(s) distribution plots in SEDFIT now revealed small amounts
of non-covalent IgA1 dimer, in distinction to our previous
distribution analyses in DCDT + sedimentation software were
unable to reveal dimers [62]. The mean IgA1 s020,w values of 6.29
S (Table 1) agreed well with previous values of 6.15–6.20 S from
DCDT + [62].
(ii) Recent instrumental advances enabled the abundant
measurement of 88 X-ray scattering curves in a single beam
session on the synchrotron (or 880 curves if time frames are
included). This wealth of data permitted the detailed study
of four different human IgA1 samples with varied O-glycan
content in physiological buffer. A newly-observed concentration-
dependence of the Rg values was seen and this was explained
by the minor IgA1 dimer formation seen by ultracentrifugation.
Accordingly, to eliminate dimer contributions to the scattering
curves, it was important to extrapolate these to zero concentration
prior to the structural modelling. In distinction, our previous X-
ray scattering study reported too few scattering runs to identify
concentration effects [24]. Also previously, pooled IgA1 samples
were used which were likely to be more polydisperse than our
present samples. Despite these differences, similar experimental
X-ray Rg, Rxs-1 and Rxs-2 values of 5.93, 2.48 and 1.58 nm were
measured for all four IgA1 samples (Table 1), compared with
previous values of 6.20, 2.20 and 1.56 nm respectively [24].
The higher previous X-ray Rg value is attributable to these
concentration effects (Figure 5A).
(iii) Our 13 neutron curves gave Rg, Rxs-1 and Rxs-2 values of
6.25, 2.13 and 1.44 nm (Table 1), compared with previous values
of 6.11, 2.17 and 1.18 nm respectively [24]. Because the neutron
Rg values were slightly higher than their corresponding X-ray
values, which were unexpected given the solute–solvent contrast
in use, the new data clarified that IgA1 in heavy water buffer
showed minor aggregation and this may be relevant to IgAN (see
below).
Our more detailed scattering modelling resulted in improved
Y-shaped IgA1 structures that replaced our previous T-shaped
structures [24]. The current modelling benefitted from extensive
experimental data, compared with the limited X-ray and neutron
data sets from before (Figures 8C and 8F of [24]). The FL3
cluster of best-fit models gave R-factors of 5.4%–5.9% (Table 2),
compared with a high R-factor of 10.9% for our previous model in
1999 [24]. The discrepancy in shape between 1999 and the current
modelling was attributed to both the concentration dependence
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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in the X-ray Rg values and the slight aggregation present in
the neutron curves, neither of which was known in 1999. This
outcome illustrates the importance of acquiring high-quality data
sets prior to performing modelling fits. When compared with the
original IgA EM studies [63–66], although some earlier studies
did not differentiate between the IgA1 and the IgA2 isotypes,
Y-shaped IgA structures were in fact observed that were flexible
at the hinge between the Fab and Fc regions. The IgA2 isotype
contains a shorter hinge region and is presumed to be less flexible
[62]. The scattering modelling of dimeric IgA1 and secretory
IgA1 also indicated Y-shaped structures and not T-shaped ones
[36,67]. Overall, Y-shaped IgA1 structures appear as its most
widely accepted consensus structure.
New insight into the variable O-galactosylated IgA1 hinges of
IgA1 resulted from the overall solution structures for the four IgA1
samples. The similarity of the hinges was shown by the similar
concentration dependences of the Rg and I(0) values (Figures 5A
and 5B), the similar s020,w values and the similar M1 and M2
values (Figures 3E, 6C and 6D). The difference curves between
the three patient and healthy subject IgA1 samples also showed no
discernible differences (Figures 7A and 7E). Atomistic modelling
for each of the four samples revealed that IgA1 has mostly (but not
fully) extended hinge structures. If the three NeuNAc.Gal.GalNAc
O-glycans at Thr225, Thr228 and Ser232 were added to the hinges
(Figure 10), the three O-glycans occupy significant surface areas
of the two hinges. The O-glycans may act as potential spacers. If
so, reductions in O-glycan contents may alter the flexibility of the
IgA1 hinges, leading to the entanglement of the hinges of different
IgA1 molecules and may pre-dispose IgA1 to its aggregation.
Interaction of human IgA1 with its FcαR receptor
Our new IgA1 solution structure clarifies its functional
interaction with FcαR receptors (CD89) on monocyte, eosinophil,
macrophage and neutrophil cell surfaces [68]. When the IgA1
models from the FL3 cluster were superimposed on to the crystal
structure of the Fc–FcαR complex, the full-sized IgA1 structure
readily accommodated two FcαR molecules (Figures 10A and
10B) [26]. This observation agrees with the 1:2 stoichiometry for
IgA1 binding to FcαR observed by surface plasmon resonance
[69]. The 1:2 IgA1–receptor complex will form at a cell surface
if there is a sufficient surface density of FcαR molecules. IgA1
binding to FcαR receptors will trigger phagocytosis, antibody-
dependent cell-mediated cytotoxicity and a respiratory burst in
neutrophils [70]. Given that the serum concentration of IgA1 is
3 mg/ml (19 μM) with 90% in the monomeric form [70] and
the dissociation constants KD for IgA1 binding to FcαR are
low between 0.18 and 0.43 μM [69], it is deduced that plasma
IgA1 will bind to surface-bound FcαR molecules. Due to the
moderately fast on- and off-rates of the FcαR–IgA1 binding
reaction (2 × 105 M·s− 1 and 0.04 s− 1 respectively) [69], rapid
sampling of free IgA1 would occur. In summary, it is expected
that a Y-shaped arrangement of Fab regions in IgA1 that coats
a pathogenic surface will result in a surface of IgA1 Fc regions
that is in the right orientation to bind to many FcαR receptors to
trigger appropriate immune responses.
Interestingly, IgA–receptor binding is very different from
IgG–receptor and IgE–receptor binding [71]. First, FcαR binds
between the Cα2 and the Cα3 domains of IgA1 away from the
hinge (Figure 10). In contrast, Fcγ R binds to IgG at the top of the
CH2 domain near the bottom of the hinge. Like IgG, FcεR binds
at the Cε2/Cε3 domain interface of IgE where the Cε2 domain
of IgE is equivalent to the IgG hinge. Second, the FcRs (Fc
receptors) generally have two-domain receptor structures, with
membrane-distal and membrane-proximal extracellular domains.
The membrane-distal domain of FcαR binds to IgA1, but, in
contrast, the membrane-proximal domains of Fcγ R and FcεR
bind to IgG and IgE respectively. Third, IgA–FcαR complexes
exhibit a 1:2 binding stoichiometry, whereas IgG–Fcγ R and
IgE–FcεR complexes exhibit 1:1 binding stoichiometries. This
is explained by the adoption of asymmetric conformations by IgG
and IgE such that the binding of one Fcγ R and FcεR receptor
molecule blocks the binding of a second receptor molecule. No
such blocking occurs in IgA1. The three O-glycans in each of the
two IgA1 hinges may be important for FcαR binding by hindering
the movement of the Fab regions that might otherwise block the
FcαR sites in the Fc region. The IgA1 tailpieces have no defined
structures, but are likely to be extended into solution and will
not block FcαR binding. Whereas IgG and IgE antibodies have to
reposition their Fab regions away from the FcR-coated cell surface
in order to permit receptor binding, there is no such requisite
displacement of the Fab regions in IgA1 when FcαR binds. Our
recent atomistic scattering modelling of the solution structures of
the IgG1 and IgG4 sub-classes extends this understanding [72,73].
Their asymmetric structures enable Fcγ R to bind to the Fc region
of IgG1 without obstructions with the Fab regions, whereas this
was not possible for Fcγ R binding to IgG4, in which the hinge
is shorter and the Fab regions will obstruct binding [72,73]. Thus
the IgG1 solution structure is already preformed to permit Fcγ R
binding.
Role of IgA1 monomers in IgAN
IgAN is a significant cause of kidney disease across the world.
Central to the pathogenesis of this common glomerulonephritis
is the formation of large circulating IgA1-containing immune
complexes that have a pre-disposition to deposit in the glomerulus
and trigger inflammation and scarring with consequent loss of
kidney function. One of the key observations in a population of
IgAN patients is the presence of poorly galactosylated IgA1 in
both the serum and the glomerular immune deposits. This
finding is consistently reproduced in populations of different
geographic origin, although there can be a considerable spread
in IgA1 O-glycan content in individual patients with kidney
biopsy-proven IgAN [9,18–20]. Changes in the hinge O-glycans
have previously been hypothesized to alter the conformation of
IgA1, thereby promoting IgA1 immune complex formation in
IgAN through IgA1 aggregation and self-association [74] and
the generation of neoepitopes, leading to the generation of IgA
and IgG hinge-region specific auto-antibodies. Even though these
immune complexes predominantly consist of polymeric IgA1, an
understanding of the structural impact of the hinge O-glycans on
IgAN firstly requires an evaluation of their impact on monomeric
IgA1.
Our experience of four IgA1 samples with variable
O-glycan contents suggests that the instability of IgA1
monomers contributes to the development of IgAN, rather than
conformational changes in IgA1. The symmetric profiles in size-
exclusion chromatography indicated that most IgA1 eluted as
stable monomers in physiological buffer (Figure 2). Nonetheless,
freezing causes IgA1 to aggregate. The low amounts (below
5%) of non-covalent IgA1 dimers seen by ultracentrifugation
(Figure 3) indicated a minor tendency for the monomer to self-
associate. Because heavy water is a known promoter of protein
self-association (because solute–solvent hydrogen bonds are
weaker in heavy water), it was of interest that IgA1 in heavy water
buffer showed slight aggregation for the two samples with higher
O-glycan contents and stronger aggregation for the two samples
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with low O-glycan contents. Because these self-association events
do not appear for human IgG1 and IgG4 [72,73], the IgA1
solution structure shows a pre-disposition to self-associate. If this
is confirmed in further biophysical investigations, this will clarify
the molecular basis of IgAN.
Postscript: atomistic modelling of antibodies
Atomistic scattering modelling offers unique views of antibody
solution structure. Only three crystal structures are available
for one human and two murine intact IgG antibodies [75,76].
Even with these, it is not assured that a single view of an
antibody immobilized in a crystal lattice will represent its
solution structure; there is a common expectation that antibodies
display many conformations in solution. The previous automated
atomistic modelling of IgA1 in 1999 was the first analysis of
its type for X-ray and neutron scattering and resulted in the
first deposition of a scattering-determined molecular structure in
the Protein Data Bank (PDB code 1IGA) [24]. In that analysis,
12000 trial randomized IgA1 structures were generated from a
MD procedure applied to the hinge peptide. The Fab and Fc
regions in these first IgA1 structures were constructed using
homology (comparative) modelling based on crystal structures
for a murine IgA Fab region and a human IgG1 Fc region. The
previous modelling assumed that the IgA1 structure would be 2-
fold symmetric about the Fc region; however, this assumption is
now no longer justified.
In the present study, the atomistic modelling of IgA1
benefitted from both the IgA1 Fab and the Fc crystal structures
[26,34] and the development of a new methodology SASSIE
to generate randomized IgA1 structures [30,31,58]. Because
earlier crystallography and scattering fits revealed that human
and mouse IgG antibodies were not necessarily 2-fold symmetric
[72,73,75,76], the assumption of symmetry was discarded for
IgA1. During model generation, a 14-fold increase from 12000
[24] to 172833 randomized hinge conformations in IgA1 was
generated by Monte Carlo variations of 20 θ and ψ angles in
the IgA1 hinge. This dihedral Monte Carlo approach is rapid and
sampled 50000 structures in less than an hour on a single CPU.
Because the hinge and Fab/Fc regions were considered together
when creating each trial IgA1 structure, steric overlaps were
handled better; poor models were now discarded at their creation,
rather than later. In addition, the combination of rapid global
structure sampling simulations and force field representations of
trial structures allowed more detailed computational studies of
IgA1 (Supplementary Figures S1–S3). The quality of the curve
fits in a Q range out to 1.25 nm− 1 (Figure 8F) with a R-factor as
low as 4.8% is improved compared with that from 1999 in a Q
range out to 2.0 nm− 1 with an R-factor of 5.4% (Figure 9B in
[24]). Both the 1999 and the current analyses resulted in similarly
extended IgA1 structures, although the detail in the current study
makes the conclusion in the present study of Y-shaped structures
more reliable. The success of the present IgA1 modelling indicates
that atomistic modelling for antibody structures has high potential
for structure–function studies of antibody–ligand complexes, as
well as for other systems.
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